—Roxadustat New Drug Applications under Review in China and Japan—
—Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019—
—Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time—
SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today reported financial results for the third quarter of 2018 and provided an update on the company’s recent developments.
“With new drug applications for roxadustat in anemia associated with chronic kidney disease supported by positive Phase 3 results and under review in China …
Source: Original Article